Fails 4 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The program pages and answers refer only to medication fulfillment, and the about page says only that every medication is made in the US in medical-grade facilities. 3 more criteria also fail; see the table below.
At a glance
TeleCareSpotTelehealth service
4/8criteria passed
Price
Semaglutide program $299 a month; tirzepatide program $399 a month
Sells
semaglutide, tirzepatide, oral tirzepatide, and 1 more
Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.
A telehealth weight loss service that prices semaglutide, tirzepatide and phentermine programs by the month after an online medical assessment and a licensed provider's review, and also lists hair loss, sexual health and mental health services. It names no company, address or pharmacy.
Operating entity No legal entity name appears in the footer, on the contact page, in the terms or in the privacy policy, which name the business only as TeleCareSpot.
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSA licensed U.S. provider reviews each online assessment, including health history and current medications, and decides whether treatment is medically appropriate before any prescription. No provider is named.Source: TeleCareSpot's website; TeleCareSpot's weight loss page; TeleCareSpot's semaglutide online page.
S2PASSThe steps are an online assessment of health history, medications and goals, then a licensed provider's review, then a treatment plan and medication only if eligible. The answers say a patient who is not approved is refunded less the consultation fee.Source: TeleCareSpot's website; TeleCareSpot's semaglutide online page; TeleCareSpot's FAQ.
S3FAILNo filling pharmacy is named. The program pages and answers refer only to medication fulfillment, and the about page says only that every medication is made in the US in medical-grade facilities.Source: TeleCareSpot's weight loss page; TeleCareSpot's FAQ; TeleCareSpot's about page.
S4FAILThe tirzepatide page sells a $399 monthly program with no statement that the medication is compounded or not FDA-approved, and the home page calls oral tirzepatide compounded with no such statement. Only an answer on the semaglutide page says compounded semaglutide is not FDA-approved.Source: TeleCareSpot's tirzepatide online page; TeleCareSpot's website; TeleCareSpot's semaglutide online page.
S5FAILNo certificate of analysis or lot document is published on the program pages, in the answers or in the terms.Source: TeleCareSpot's weight loss page; TeleCareSpot's FAQ; TeleCareSpot's terms and conditions.
S6FAILNo postal address and no company name appear on the contact page, in the footer, in the terms or in the privacy policy, which give only an email address and name the laws of the USA.Source: TeleCareSpot's contact page; TeleCareSpot's terms and conditions; TeleCareSpot's privacy policy.
S7PASSThe semaglutide program costs $299 a month and the tirzepatide program $399 a month, each including the evaluation, provider support and the medication if prescribed, and the phentermine program costs from $189 a month. A 20-minute consultation costs $79 one time and may be applied toward a program. The answers instead say programs typically range from $199 to $499 a month.Source: TeleCareSpot's weight loss page; TeleCareSpot's semaglutide online page; TeleCareSpot's tirzepatide online page; TeleCareSpot's FAQ.
S8PASSNo FDA warning letter names TeleCareSpot, and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide, oral tirzepatide, phentermine.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.